Literature DB >> 12706695

Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV.

Antonia Radaelli1, Carlo Zanotto, Gianpaolo Perletti, Veronica Elli, Elisa Vicenzi, Guido Poli, Carlo De Giuli Morghen.   

Abstract

Three different prime-boost immunization protocols were tested in rabbits and their immune response was evaluated and compared with the final aim of identifying a vaccine strategy that might be able to protect non-human primates from infection with the pathogenic chimera simian/human immunodeficiency virus (SHIV)(89.6P). Protocols were based on priming with two fowlpox (FP) recombinant vectors and two expression plasmids, which express either the simian immunodeficiency virus (SIV)mac(239) gag/pol or the human immunodeficiency virus (HIV-1)env(89.6P) genes, followed by boosting with virus-like particles (VLP). All protocols were effective in eliciting homologous neutralizing Ab and highlighted the efficacy of VLP boosting. The FP vector was less efficient than plasmid DNA in inducing Ab against the gag core proteins. Analysis of cytokine expression 5 months after last immunization indicated that priming with pcDNA3gag/pol(SIV) and FPenv(89.6P) followed by VLP boosting generated a T helper (Th0) profile and a good Ab titer, suggesting a potential protocol to be tested in the SHIV-macaque model of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706695     DOI: 10.1016/s0264-410x(02)00773-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Poxvirus vectors as HIV/AIDS vaccines in humans.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Juan Garcia-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

2.  Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.

Authors:  Jason Hammonds; Xuemin Chen; Timothy Fouts; Anthony DeVico; David Montefiori; Paul Spearman
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits.

Authors:  Antonia Radaelli; Eleana Pozzi; Sole Pacchioni; Carlo Zanotto; Carlo De Giuli Morghen
Journal:  J Transl Med       Date:  2010-04-21       Impact factor: 5.531

4.  Characterization of host responses against a recombinant fowlpox virus-vectored vaccine expressing the hemagglutinin antigen of an avian influenza virus.

Authors:  Hamid R Hghihghi; Leah R Read; Hakimeh Mohammadi; Yanlong Pei; Claudia Ursprung; Eva Nagy; Shahriar Behboudi; S M Mansour Haeryfar; Shayan Sharif
Journal:  Clin Vaccine Immunol       Date:  2010-01-13

5.  Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein.

Authors:  Carlo Zanotto; Eleana Pozzi; Sole Pacchioni; Massimiliano Bissa; Carlo De Giuli Morghen; Antonia Radaelli
Journal:  J Transl Med       Date:  2011-11-04       Impact factor: 5.531

6.  Construction of a recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine.

Authors:  Antonia Radaelli; Carlo De Giuli Morghen; Carlo Zanotto; Francesca Paolini
Journal:  Virol J       Date:  2021-03-04       Impact factor: 4.099

7.  Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4+ and CD8+ T-Cell Responses.

Authors:  Ulrike Sauermann; Antonia Radaelli; Nicole Stolte-Leeb; Katharina Raue; Massimiliano Bissa; Carlo Zanotto; Michael Krawczak; Matthias Tenbusch; Klaus Überla; Brandon F Keele; Carlo De Giuli Morghen; Sieghart Sopper; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2017-11-14       Impact factor: 6.549

Review 8.  Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV.

Authors:  Sarah Wilmschen; Joern E Schmitz; Janine Kimpel
Journal:  Vaccines (Basel)       Date:  2019-09-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.